keyword
https://read.qxmd.com/read/24300002/diffusion-weighted-magnetic-resonance-imaging-and-adc-maps-in-the-diagnosis-of-intracranial-cystic-or-necrotic-lesions-a-retrospective-study-on-49-patients
#21
JOURNAL ARTICLE
S Greco Crasto, R Soffietti, R Rudà, P Cassoni, A Ducati, O Davini, R De Lucchi, L Rizzo
This study evaluated the usefulness of diffusion-weighted (DW) magnetic resonance imaging (MRI) and ADC maps in the differential diagnosis of brain abscesses from cystic or necrotic neoplasms. MR images of 49 patients with 54 lesions were examined retrospectively. All patients underwent conventional MRI and DWI, and ADC values were calculated by placing ROIs of 30 mm(2) manually over the cystic part of the lesions. On DWI, all cystic portions of abscesses were hyperintense. Mean ADC values were 0.48×10 mm(2)/s (range 0...
December 31, 2007: Neuroradiology Journal
https://read.qxmd.com/read/23993385/challenges-relating-to-solid-tumour-brain-metastases-in-clinical-trials-part-2-neurocognitive-neurological-and-quality-of-life-outcomes-a-report-from-the-rano-group
#22
REVIEW
Nancy U Lin, Jeffrey S Wefel, Eudocia Q Lee, David Schiff, Martin J van den Bent, Riccardo Soffietti, John H Suh, Michael A Vogelbaum, Minesh P Mehta, Janet Dancey, Mark E Linskey, D Ross Camidge, Hidefumi Aoyama, Paul D Brown, Susan M Chang, Steven N Kalkanis, Igor J Barani, Brigitta G Baumert, Laurie E Gaspar, F Stephen Hodi, David R Macdonald, Patrick Y Wen
Neurocognitive function, neurological symptoms, functional independence, and health-related quality of life are major concerns for patients with brain metastases. The inclusion of these endpoints in trials of brain metastases and the methods by which these measures are assessed vary substantially. If functional independence or health-related quality of life are planned as key study outcomes, then the reliability and validity of these endpoints can be crucial because methodological issues might affect the interpretation and acceptance of findings...
September 2013: Lancet Oncology
https://read.qxmd.com/read/23993384/challenges-relating-to-solid-tumour-brain-metastases-in-clinical-trials-part-1-patient-population-response-and-progression-a-report-from-the-rano-group
#23
REVIEW
Nancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, Igor J Barani, Brigitta G Baumert, Paul D Brown, D Ross Camidge, Susan M Chang, Janet Dancey, Laurie E Gaspar, Gordon J Harris, F Stephen Hodi, Steven N Kalkanis, Kathleen R Lamborn, Mark E Linskey, David R Macdonald, Kim Margolin, Minesh P Mehta, David Schiff, Riccardo Soffietti, John H Suh, Martin J van den Bent, Michael A Vogelbaum, Jeffrey S Wefel, Patrick Y Wen
Therapeutic outcomes for patients with brain metastases need to improve. A critical review of trials specifically addressing brain metastases shows key issues that could prevent acceptance of results by regulatory agencies, including enrolment of heterogeneous groups of patients and varying definitions of clinical endpoints. Considerations specific to disease, modality, and treatment are not consistently addressed. Additionally, the schedule of CNS imaging and consequences of detection of new or progressive brain metastases in trials mainly exploring the extra-CNS activity of systemic drugs are highly variable...
September 2013: Lancet Oncology
https://read.qxmd.com/read/23452038/histological-predictors-of-outcome-in-ependymoma-are-dependent-on-anatomic-site-within-the-central-nervous-system
#24
JOURNAL ARTICLE
Aditya Raghunathan, Khalida Wani, Terri S Armstrong, Elizabeth Vera-Bolanos, Maryam Fouladi, Richard Gilbertson, Amar Gajjar, Stewart Goldman, Norman L Lehman, Phillipe Metellus, Tom Mikkelsen, Mary Jo T Necesito-Reyes, Antonio Omuro, Roger J Packer, Sonia Partap, Ian F Pollack, Michael D Prados, H Ian Robins, Riccardo Soffietti, Jing Wu, C Ryan Miller, Mark R Gilbert, Kenneth D Aldape
Ependymomas originate in posterior fossa (PF), supratentorial (ST) or spinal cord (SC) compartments. At present, grading schemes are applied independent of anatomic site. We performed detailed histological examination on 238 World Health Organization grade II and III ependymomas. Among PF ependymomas, the presence of hypercellular areas, necrosis, microvascular proliferation and elevated mitotic rate (all P < 0.01) were significantly associated with worse progression-free survival (PFS), while extensive ependymal canal formation was not (P = 0...
September 2013: Brain Pathology
https://read.qxmd.com/read/22322993/a-prognostic-gene-expression-signature-in-infratentorial-ependymoma
#25
JOURNAL ARTICLE
Khalida Wani, Terri S Armstrong, Elizabeth Vera-Bolanos, Aditya Raghunathan, David Ellison, Richard Gilbertson, Brian Vaillant, Stewart Goldman, Roger J Packer, Maryam Fouladi, Ian Pollack, Tom Mikkelsen, Michael Prados, Antonio Omuro, Riccardo Soffietti, Alicia Ledoux, Charmaine Wilson, Lihong Long, Mark R Gilbert, Ken Aldape
Patients with ependymoma exhibit a wide range of clinical outcomes that are currently unexplained by clinical or histological factors. Little is known regarding molecular biomarkers that could predict clinical behavior. Since recent data suggest that these tumors display biological characteristics according to their location (cerebral vs. infratentorial vs. spinal cord), rather than explore a broad spectrum of ependymoma, we focused on molecular alterations in ependymomas arising in the infratentorial compartment...
May 2012: Acta Neuropathologica
https://read.qxmd.com/read/22230531/brain-metastases
#26
REVIEW
R Soffietti, A Ducati, R Rudà
No abstract text is available yet for this article.
2012: Handbook of Clinical Neurology
https://read.qxmd.com/read/22230511/low-grade-gliomas
#27
REVIEW
R Rudà, E Trevisan, R Soffietti
No abstract text is available yet for this article.
2012: Handbook of Clinical Neurology
https://read.qxmd.com/read/22229250/anti-angiogenic-approaches-to-malignant-gliomas
#28
REVIEW
R Soffietti, E Trevisan, L Bertero, C Bosa, R Ruda
Despite advances in multidisciplinary approaches, the prognosis for most patients with malignant gliomas is poor. Malignant gliomas are highly vascularized tumors with elevated expression of vascular endothelial growth factor (VEGF), an important mediator of angiogenesis. Recent studies of bevacizumab, an anti-VEGF monoclonal antibody, alone or associated with chemotherapy, have demonstrated high response rates and prolongation of median and 6-month progression-free survival. Clinical evaluation of several multitarget small molecule tyrosine kinase inhibitors is ongoing...
March 2012: Current Cancer Drug Targets
https://read.qxmd.com/read/20880069/screening-for-tumours-in-paraneoplastic-syndromes-report-of-an-efns-task-force
#29
JOURNAL ARTICLE
M J Titulaer, R Soffietti, J Dalmau, N E Gilhus, B Giometto, F Graus, W Grisold, J Honnorat, P A E Sillevis Smitt, R Tanasescu, C A Vedeler, R Voltz, J J G M Verschuuren
BACKGROUND: paraneoplastic neurological syndromes (PNS) almost invariably predate detection of the malignancy. Screening for tumours is important in PNS as the tumour directly affects prognosis and treatment and should be performed as soon as possible. OBJECTIVES: an overview of the screening of tumours related to classical PNS is given. Small cell lung cancer, thymoma, breast cancer, ovarian carcinoma and teratoma and testicular tumours are described in relation to paraneoplastic limbic encephalitis, subacute sensory neuronopathy, subacute autonomic neuropathy, paraneoplastic cerebellar degeneration, paraneoplastic opsoclonus-myoclonus, Lambert-Eaton myasthenic syndrome (LEMS), myasthenia gravis and paraneoplastic peripheral nerve hyperexcitability...
January 2011: European Journal of Neurology
https://read.qxmd.com/read/20718851/guidelines-on-management-of-low-grade-gliomas-report-of-an-efns-eano-task-force
#30
JOURNAL ARTICLE
R Soffietti, B G Baumert, L Bello, A von Deimling, H Duffau, M Frénay, W Grisold, R Grant, F Graus, K Hoang-Xuan, M Klein, B Melin, J Rees, T Siegal, A Smits, R Stupp, W Wick
BACKGROUND: Diffuse infiltrative low-grade gliomas of the cerebral hemispheres in the adult are a group of tumors with distinct clinical, histological and molecular characteristics, and there are still controversies in management. METHODS: The scientific evidence of papers collected from the literature was evaluated and graded according to EFNS guidelines, and recommendations were given accordingly. RESULTS AND CONCLUSIONS: WHO classification recognizes grade II astrocytomas, oligodendrogliomas and oligoastrocytomas...
September 2010: European Journal of Neurology
https://read.qxmd.com/read/20425040/ependymomas-in-adults
#31
REVIEW
Mark R Gilbert, Roberta Ruda, Riccardo Soffietti
Ependymomas are rare primary central nervous system tumors in adults. They occur most commonly in the spinal cord, where histopathologic evaluation is critical to differentiate the grade I myxopapillary ependymoma from the grade II ependymoma or grade III anaplastic ependymoma. Brain ependymomas are either grade II or III. Treatment for all grades and types includes maximum surgical resection. For myxopapillary ependymoma, complete removal while maintaining capsule integrity may be curative. Some grade II ependymomas may be observed carefully after imaging confirms complete resection, but grade III tumors require adjuvant radiation treatment...
May 2010: Current Neurology and Neuroscience Reports
https://read.qxmd.com/read/18699850/the-addition-of-rituximab-to-anthracycline-based-chemotherapy-significantly-improves-outcome-in-western-patients-with-intravascular-large-b-cell-lymphoma
#32
MULTICENTER STUDY
Andrés J M Ferreri, Giuseppina P Dognini, Osnat Bairey, Arpad Szomor, Carlos Montalbán, Barbara Horvath, Judit Demeter, Lilj Uziel, Riccardo Soffietti, John F Seymour, Achille Ambrosetti, Rein Willemze, Maurizio Martelli, Giuseppe Rossi, Anna Candoni, Amalia De Renzo, Claudio Doglioni, Emanuele Zucca, Franco Cavalli, Maurilio Ponzoni et al.
Some case reports and a Japanese series suggest benefit from the use of rituximab in patients with intravascular large B-cell lymphoma (IVL). Rituximab efficacy was evaluated in Western patients with IVL, comparing outcome of 10 patients treated with rituximab + chemotherapy (R-CT) and of 20 patients treated with chemotherapy alone (CT). There were no significant differences in patients' characteristics between the two subgroups. The addition of rituximab was associated with improved complete remission rate (90% vs...
October 2008: British Journal of Haematology
https://read.qxmd.com/read/18293027/natural-history-and-management-of-brainstem-gliomas-in-adults-a-retrospective-italian-study
#33
JOURNAL ARTICLE
A Salmaggi, L Fariselli, I Milanesi, E Lamperti, A Silvani, A Bizzi, E Maccagnano, E Trevisan, E Laguzzi, R Rudà, A Boiardi, R Soffietti
Brainstem gliomas in adults are rare tumors, with heterogeneous clinical course; only a few studies in the MRI era describe the features in consistent groups of patients. In this retrospective study, we report clinical features at onset, imaging characteristics and subsequent course in a group of 34 adult patients with either histologically proven or clinico-radiologically diagnosed brainstem gliomas followed at two centers in Northern Italy. Of the patients 18 were male, 14 female, with a median age of 31...
February 2008: Journal of Neurology
https://read.qxmd.com/read/16990655/endocrine-dysfunction-in-patients-operated-on-for-non-pituitary-intracranial-tumors
#34
JOURNAL ARTICLE
H J Schneider, S Rovere, G Corneli, C G Croce, V Gasco, R Rudà, S Grottoli, G K Stalla, R Soffietti, E Ghigo, G Aimaretti
OBJECTIVE: Hypopituitarism frequently follows pituitary neurosurgery (NS) and/or irradiation. However, the frequency of hypothalamic-pituitary dysfunction after NS of non-pituitary intracranial tumors is unclear. The aim of this study was to assess the presence of endocrine alterations in patients operated on for intracranial tumors. DESIGN: This is a retrospective study. METHODS: We studied 68 consecutive adult patients (28 female, 40 male, age 45...
October 2006: European Journal of Endocrinology
https://read.qxmd.com/read/16834697/efns-guidelines-on-diagnosis-and-treatment-of-brain-metastases-report-of-an-efns-task-force
#35
JOURNAL ARTICLE
R Soffietti, P Cornu, J Y Delattre, R Grant, F Graus, W Grisold, J Heimans, J Hildebrand, P Hoskin, M Kalljo, P Krauseneck, C Marosi, T Siegal, C Vecht
The objectives have been to establish evidence-based guidelines and identify controversies regarding the management of patients with brain metastases. The collection of scientific data was obtained by consulting the Cochrane Library, bibliographic databases, overview papers and previous guidelines from scientific societies and organizations. A tissue diagnosis is necessary when the primary tumor is unknown or the aspect on computed tomography/magnetic resonance imaging is atypical. Dexamethasone is the corticosteroid of choice for cerebral edema...
July 2006: European Journal of Neurology
https://read.qxmd.com/read/16215814/radiotherapy-and-chemotherapy-of-brain-metastases
#36
REVIEW
R Soffietti, A Costanza, E Laguzzi, M Nobile, R Rudà
The authors have reviewed the results, the indications and the controversies regarding radiotherapy and chemotherapy of patients with newly diagnosed and recurrent brain metastases. Whole-brain radiotherapy, radiosurgery, hypofractionated stereotactic radiotherapy, brachytherapy and chemotherapy are the available options. New radiosensitizers and cytotoxic or cytostatic agents are being investigated. Adjuvant whole brain radiotherapy, either after surgery or radiosurgery, and prophylactic cranial irradiation in small-cell lung cancer are discussed, taking into account local control, survival, and risk of late neurotoxicity...
October 2005: Journal of Neuro-oncology
https://read.qxmd.com/read/11985627/the-position-of-the-neurologist-in-neuro-oncology
#37
REVIEW
W Grisold, J J Heimans, T J Postma, R Grant, R Soffietti
Neuro-oncology is a growing new subspeciality with a strong interdisciplinary character. This position paper explains the role of neurology in the multidisciplinary field of neurosurgeons, radiotherapists and general oncologists, dealing with neuro-oncological patients. The paper delineates the varied spectrum of the field of neuro-oncology which expands from primary brain tumours, to metastatic and non-metastatic effects of systemic cancer on the central and peripheral nervous system, neurotoxicity due to cancer treatment and issues of quality of life...
May 2002: European Journal of Neurology
https://read.qxmd.com/read/11512393/-cerebral-metastatis-diagnostic-and-therapeutic-features
#38
REVIEW
R Soffietti, R Rudà, M Nobile
Brain metastases represent the most frequent intracranial neoplasms in adults: between 15 and 25% of patients with systemic tumors will face brain metastases along the clinical course of disease. Lung cancers, breast cancers and melanomas are the commonest causes of brain metastases (about 75%), while the primary site remains unknown inasmuch as 15% of cases. Headache, focal neurological deficits, epilepsy and intracranial hypertension are the most frequent initial symptoms and signs. Computerized Tomography and Magnetic Resonance represent the methods of choice for diagnosis...
June 2000: Recenti Progressi in Medicina
https://read.qxmd.com/read/11437161/brain-metastases-from-unknown-primary-tumour-a-prospective-study
#39
JOURNAL ARTICLE
R Rudà, M Borgognone, F Benech, E Vasario, R Soffietti
The best management of patients with brain metastases from an unknown primary tumour is still unclear, as data are scarce and studies are retrospective. We report 33 patients with biopsy-proven brain metastases from a primary tumour not found at the first investigations, who were treated by surgery and/or radiotherapy and followed with serial CT until death. Median survival time for all patients was 10 months and survival rates at 6 months, 1 year and 2 years were 76 %, 42 % and 15 % respectively. Patients with single brain metastasis treated by gross total resection and whole-brain radiotherapy (WBRT) had a median survival of 13 months with 76% alive at 6 months, 57 % at 1 year and 19% at 2 years...
May 2001: Journal of Neurology
https://read.qxmd.com/read/11311915/primitive-cerebral-melanoma-case-report-and-review-of-the-literature
#40
REVIEW
S Greco Crasto, R Soffietti, G B Bradac, R Boldorini
BACKGROUND: Central nervous system primary malignant melanoma accounts for approximately 1% of all the cases of melanoma; reports in the literature are relatively rare. CASE DESCRIPTION: A 74-year-old man was hospitalized because of an episode of aphasia. The neuroradiologic examinations demonstrated a round homogeneous lesion extending near the left sylvian fissure. He had no extracranial abnormalities. The patient underwent a neurosurgical procedure and the tumor was macroscopically totally excised...
March 2001: Surgical Neurology
keyword
keyword
17832
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.